inflamed.communityinflamed.community

Refinement of the Pathogenic T Cell Receptor Motif Suggests Type 17 CD8+ T Cells Initiate HLA-B*27-associated Autoimmunity.

Risch I · 2026 · bioRxiv : the preprint server for biology

Reading the original? How to read a paper.

What this paper found

A specific family of killer T cells that recognise HLA-B27 was found in people with axial spondyloarthritis, uveitis and psoriatic arthritis but not healthy controls, and these cells appear to switch into an IL-17-producing mode in the gut. It is a direct line from the HLA-B27 gene, through the gut, to the inflammation that IL-17 drugs block, in one set of cells.

Why this is on the map

Ties three threads together with a single cell type; a preprint, so not yet peer reviewed.

On the map under these threads

Read the paper at the source →

DOI: 10.64898/2026.09.18.752092 · opens in a new tab. The full paper is on the publisher’s site, not here.

Related papers on the board

Papers sharing one or more threads with this one.

Stankey · 2024
Study

A disease-associated gene desert directs macrophage inflammation through ETS2

Nature

Identified a single 'switch' gene called ETS2, sitting on chromosome 21, that turns immune cells inflammatory across AS, IBD, and several other related diseases. Because no current drug targets ETS2, this points to a treatment direction beyond what's already available with TNF and IL-17 blockers.

ETS2 / Functional GenomicsMacrophage M1 PolarisationIL-23 / IL-17 Axis
Huang · 2026
Study

HLA-B27-associated gut microbiota and amino acid perturbations promote ankylosing spondylitis through M1 macrophage activation

Gut Microbes

Shows that HLA-B27, the gene most strongly linked to AS, reshapes which bacteria live in the gut and how the body handles certain amino acids, which in turn activates the inflammatory immune cells driving the disease. Suggests targeting the gut and these metabolic changes could become a real treatment route.

Gut–Immune AxisMacrophage M1 PolarisationHLA-B27 Genetics
Lobiuc · 2025
Review

Gut microbiota and ankylosing spondylitis: current insights and future challenges

Microbial Cell

Comprehensive review of how gut bacterial imbalance disrupts the IL-23/IL-17 inflammatory pathway and weakens the intestinal barrier in AS. Identifies the lack of standardised methodology and large cohorts as the bottleneck for translating this into treatments.

Gut–Immune AxisIL-23 / IL-17 Axis
, · 2025
Study

Dysbiosis of Gut Microbiota in Ankylosing Spondylitis Patients

Dove Medical Press

Confirms that intestinal dysfunction precedes or amplifies systemic inflammation in AS. Frames gut microbiota as the convergence point where genetic, immune, and microbial factors meet.

Gut–Immune AxisIL-23 / IL-17 Axis